Roth Capital Upgrades Alpha Teknova (NASDAQ:TKNO) to Strong-Buy

Key Points

• Roth Capital upgraded Alpha Teknova to “strong buy,” but analyst sentiment remains mixed, with Weiss Ratings maintaining a “sell (D-)” rating. The consensus rating is “Hold,” with a target price of $7.00.
• Alpha Teknova reported quarterly EPS of -$0.06, beating estimates by $0.02, while revenue of $12.19 million exceeded expectations of $10.95 million. Despite the beat, the company posted a negative net margin of 41.07%.
• TKNO shares opened at $5.61, up substantially from their 12-month low of $1.91 and near the $6.68 high. Hedge funds and institutional investors own approximately 13.81% of the company.

Alpha Teknova (NASDAQ:TKNO - Get Free Report) was upgraded by equities research analysts at Roth Capital to a "strong-buy" rating in a note issued to investors on Wednesday,Zacks.com reports.

Separately, Weiss Ratings reissued a "sell (d-)" rating on shares of Alpha Teknova in a report on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Alpha Teknova presently has a consensus rating of "Hold" and a consensus target price of $7.00.

Alpha Teknova Price Performance

Shares of TKNO opened at $5.61 on Wednesday. The firm has a market capitalization of $300.75 million, a price-to-earnings ratio of -17.53 and a beta of 0.64. The firm's fifty day simple moving average is $5.17 and its 200-day simple moving average is $3.71. Alpha Teknova has a twelve month low of $1.91 and a twelve month high of $6.68. The company has a current ratio of 4.59, a quick ratio of 3.60 and a debt-to-equity ratio of 0.20.

Alpha Teknova (NASDAQ:TKNO - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.02. The company had revenue of $12.19 million for the quarter, compared to analyst estimates of $10.95 million. Alpha Teknova had a negative return on equity of 24.32% and a negative net margin of 41.07%.

Hedge Funds Weigh In On Alpha Teknova

Large investors have recently added to or reduced their stakes in the business. Walleye Capital LLC purchased a new position in Alpha Teknova during the second quarter worth approximately $263,000. Roubaix Capital LLC boosted its position in Alpha Teknova by 88.5% in the 1st quarter. Roubaix Capital LLC now owns 1,882,355 shares of the company's stock valued at $5,440,000 after buying an additional 883,823 shares during the last quarter. R Squared Ltd acquired a new position in shares of Alpha Teknova in the first quarter worth about $42,000. XTX Topco Ltd purchased a new position in Alpha Teknova in the fourth quarter valued at about $77,000. Finally, Marshall Wace LLP grew its stake in Alpha Teknova by 286.1% during the 4th quarter. Marshall Wace LLP now owns 50,156 shares of the company's stock valued at $191,000 after purchasing an additional 37,164 shares in the last quarter. 13.81% of the stock is currently owned by hedge funds and other institutional investors.

About Alpha Teknova

Alpha Teknova, Inc NASDAQ: TKNO is a life science tools and reagents company that develops, manufactures and distributes proprietary products to support research, drug discovery and biomanufacturing. Its offerings target academic institutions, pharmaceutical and biotechnology firms, and diagnostic developers, with a focus on high-purity reagents and optimized workflows designed to accelerate molecular biology and protein science applications.

The company's portfolio includes molecular biology reagents, cell culture buffers, in vitro translation kits, custom recombinant proteins, high-throughput screening buffers and other specialized formulations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source